George Grossberg, MD
Psychiatry · Saint Louis, MONPI 1033135991
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Otsuka Pharmaceutical Co., Ltd. at 33.3% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $1408.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Co., Ltd.$167K
- Acadia Pharmaceuticals Inc$83K
- Eisai Inc.$62K
- Otsuka America Pharmaceutical, Inc.$42K
- H. Lundbeck A S$40K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$34K
- plus $72K from 12 others
Across 4 payments — averaging $4988.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$16K
- Eli Lilly$2K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$197,47739%
- Speaking & faculty fees$150,53130%
- Travel & lodging$147,84229%
- Food & beverage$5,3351%
- Education$2720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 64 | $167,041 |
| Acadia Pharmaceuticals Inc | 68 | $83,197 |
| Eisai Inc. | 56 | $62,197 |
| Otsuka America Pharmaceutical, Inc. | 39 | $42,446 |
| H. Lundbeck A S | 20 | $39,716 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 36 | $34,394 |
| E.r. Squibb & Sons, L.L.C. | 8 | $15,457 |
| Genentech USA, Inc. | 9 | $10,861 |
| Lundbeck LLC | 17 | $10,258 |
| Axsome Therapeutics, Inc. | 18 | $10,042 |
| Biogen | 5 | $7,373 |
| Avanir Pharmaceuticals, Inc. | 1 | $7,350 |
| Grifols Shared Services North America, Inc. | 7 | $5,667 |
| Roche Diagnostics Corporation | 1 | $2,900 |
| Merck | 2 | $2,325 |
| Lilly USA, LLC | 2 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Alkermes, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$279,306
- NUPLAZID$60,757
- Leqembi$54,286
- DISEASE EDUCATION$14,050
- Albutein$4,608
- BRINTELLIX$3,453
- ADUHELM$1,740
- Flebogamma DIF$965
How this compares
$501,457 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $33,796 |
| MyrbetriqMirabegron | 41 | $16,486 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $14,391 |
| Lurasidone Hcl | 12 | $12,419 |
| Rivastigmine | 115 | $12,108 |
| ViibrydVilazodone Hcl | 20 | $12,028 |
| Aripiprazole | 77 | $5,156 |
| Vilazodone Hcl | 51 | $3,200 |
| Memantine Hcl | 172 | $3,010 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 80 | $2,725 |
| Trazodone Hcl | 169 | $2,264 |
| Methylphenidate Hcl | 81 | $2,119 |
| Clozapine | 45 | $2,103 |
| Duloxetine Hcl | 86 | $2,065 |
| Quetiapine Fumarate | 135 | $1,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $42,446 | $33,79624 claims |
| Axsome Therapeutics, Inc.Auvelity | $10,042 | $14,39112 claims |
| Lilly USA, LLCOlanzapine | $154 | $62123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
- Eric LenzeSaint Louis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.